Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB EBITDA Margin

EBITDA as a percentage of revenue.

Standard BioTools Inc.NASDAQ: LAB

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -62.5%

EBITDA Margin was -62.5% in Q1 FY2026, up 33.1 pp from a year earlier. On a trailing-twelve-month basis it was -94.5%, down 30.2 pp year over year. Over 3 fiscal years it widened by 72.1 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -31.2% for the fiscal year ending Dec 2026, up from -105.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-62.5%+24.7 pp QoQ
Last fiscal yearDec 2025
-105.1%-37.4 pp YoY
LTMMar 2026
-94.5%-30.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+33.1 pp+56.8 pp+23.7 pp
1 year-37.4 pp+73.9 pp+111.3 pp
3 years+72.1 pp+55.4 pp-16.7 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-105.1%
Year-over-year change
-37.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How LAB compares with its peers on the latest reported figures

  • LAB's LTM Mar 2026 EBITDA Margin of -94.5% is the 9th highest of the 10 companies compared; the peer median is -10.8%.
  • Its year-over-year change of -30.2 pp is the lowest of 10, against a peer median of -2.1 pp.
  • Over three fiscal years its change of +72.1 pp compares with a peer median of -9.1 pp.
LAB Competitors Peer median
EBITDA Margin for LAB and competitors
Company Period LTM level YoY 3-year change
BVSBioventus Inc.LTM Mar 202617.9% +11.6 pp+41.2 pp
VREXVarex Imaging CorporationLTM Apr 2026-0.7% -9.9 pp-12.9 pp
KIDSOrthoPediatrics Corp.LTM Mar 2026-2.7% +3.5 pp+2.1 pp
AVNSAvanos Medical, Inc.LTM Mar 2026-3.0% +46.3 pp-16.1 pp
CTKBCytek Biosciences, Inc.LTM Mar 2026-10.8% -4.7 pp-14.4 pp
SYSo-Young International Inc.LTM Mar 2026-12.3% -11.0 pp-9.1 pp
TMCITreace Medical Concepts, Inc.LTM Mar 2026-22.3% -4.0 pp+5.3 pp
CBLLCeriBell, Inc.LTM Mar 2026-60.2% -2.1 pp+78.9 pp
LABStandard BioTools Inc.LTM Mar 2026-94.5% -30.2 pp+72.1 pp
ADCTADC Therapeutics S.A.LTM Mar 2026-105.1% +22.1 pp-58.4 pp
CGEMCullinan Therapeutics, Inc.FY2025— ——
Peer median (excluding LAB) -10.8%-2.1 pp-9.1 pp

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.58M97.95M106.34M174.43M85.33M
Cost of Revenue61.21M60.9M55.89M90.17M42.79M
Gross Profit69.37M37.05M50.45M84.26M42.54M
Gross Margin53.1%37.8%47.4%48.3%49.9%
Research & Development37.94M37.38M25.95M62.41M25.99M
Selling, General & Admin98.89M102.29M87.54M156.61M109.86M
Operating Expenses136.83M153.26M127.05M259.5M135.85M
Depreciation & Amortization15.57M15.03M15.18M16.86M6.98M
EBITDA(44.27M)(173.57M)(54.46M)(118.14M)(89.69M)
EBITDA Margin-33.9%-177.2%-51.2%-67.7%-105.1%
Operating Income(67.46M)(116.21M)(76.6M)(175.24M)(93.31M)
Operating Margin-51.7%-118.6%-72.0%-100.5%-109.3%
Interest Income02.23M5.57M20.2M9.18M
Interest Expense3.82M4.33M4.57M3.32M26K
Other Income / Expenses3.8M(76.72M)2.4M36.92M(3.4M)
Income Before Tax(63.66M)(192.93M)(74.2M)(138.31M)(96.7M)
Pre-Tax Margin-48.8%-197.0%-69.8%-79.3%-113.3%
Income Tax Expense(4.42M)(2.83M)452K573K(37.88M)
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Net Margin-45.4%-194.1%-70.2%-79.6%-87.8%
EPS (Basic)(0.78)(2.43)(0.94)(0.52)(0.20)
EPS (Diluted)(0.78)(2.43)(0.94)(0.52)(0.20)
Weighted Avg Shares75.79M78.31M79.16M352.67M381.62M
Weighted Avg Shares (Diluted)75.79M78.31M79.16M352.67M381.62M

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.